Berberine as a Natural Metabolic Modulator: A Comprehensive Review of Its Role in Diabetes, Obesity, and cardiovascular diseases
DOI:
https://doi.org/10.59675/U412Keywords:
Berberine, meta-syndrome, diabetes mellitus, obesity, cardiovascular disease, AMPK activation, natural compounds, herbal medicine.Abstract
Berberine is an isoquinoline alkaloid extracted from a variety of plant species, particularly members of the genus Berberis, which has been studied extensively in terms of its therapeutic action in metabolic disorders. The incidence of metabolic diseases such as diabetes mellitus, obesity and cardiovascular diseases has been one of the serious health problems in the world demanding effective therapies. Natural products that possess positive safety profiles have been of growing interest as therapeutic compounds. Research Question: How do the molecular processes and clinical effectiveness of berberine in diabetes mellitus, obesity and cardiovascular diseases work? Methods: A literature review was carried out with the help of various databases such as PubMed, Scopus, and Web of Science, where the works released during the period between 2018 and 2025 were selected. Several mechanisms by which berberine mediates its metabolic actions were investigated, such as the activation of AMP-activated protein kinase [AMPK], alteration of glucose and lipid metabolism, anti-inflammatory effects and alteration of the gut microbiota composition. The review summarized the available evidence on preclinical research and clinical trials. Findings: It was shown that Berberine has strong hypoglycemic and hypolipidemic as well as cardio protective properties. Berberine was demonstrated to have similar efficacy in the management of diabetes as metformin in the reduction of the fasting blood glucose, the increase of the insulin sensitivity, and the improvement of the glycemic control. In the treatment of obesity, berberine was shown to have the capacity to reduce body mass, reduce fat deposition, and regulate the release of adipokines in a variety of ways. Cardiovascular effects were the decrease in total cholesterol, low-density lipoprotein cholesterol, and triglycerides, as well as the enhancement of endothelial function. The commonly reported effects were mild gastrointestinal effects with a positive safety profile. Although it had promising outcomes, it was found to be limited by the unfavorable intestinal absorption [0.5-2% bioavailability] and inconsistent clinical reactions. Conclusion: Berberine is a potentially effective natural metabolic modulator that has been shown to be effective in several metabolic diseases. Future research directions are focused on the necessity of large-scale randomized controlled trials, optimization of formulations to increase bioavailability, and the study of combination therapies to allow reaching a high therapeutic potential.
References
1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes research and clinical practice. 2019 Nov 1; 157:107843.
2. NCD Risk Factor Collaboration. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390[10113]:2627-2642.
3. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. Journal of the American college of cardiology. 2020 Dec 22;76(25):2982-3021.
4. Bailey CJ, Turner RC. Metformin. New England Journal of Medicine. 1996 Feb 29;334(9):574-9.
5. Chao WW, Lin BF. Bioactivities of major constituents isolated from Angelica sinensis [Danggui]. Chin Med. 2011; 6:29.
6. Singh IP, Mahajan S. Berberine and its derivatives: a patent review [2009-2012]. Expert Opin Ther Pat. 2013;23[2]:215-231.
7. Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res. 2008;22[8]:999-1012.
8. Neag MA, Mocan A, Echeverría J, Pop RM, Bocsan CI, Crişan G, Buzoianu AD. Berberine: Botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. Frontiers in pharmacology. 2018 Aug 21; 9:557.
9. Yao J, Kong W, Jiang J. Learning from berberine: Treating chronic diseases through multiple targets. Sci China Life Sci. 2015;58[9]:854-859.
10. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006 Aug 1;55(8):2256-64.
11. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, Taketo MM, Cooney GJ, Kraegen EW, James DE, Hu LH. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008 May 1;57(5):1414-8.
12. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. The Journal of Clinical Endocrinology & Metabolism. 2008 Jul 1;93(7):2559-65.
13. Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, Kim WS, Kim JB. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. American Journal of Physiology-Endocrinology and Metabolism. 2009 Apr;296(4):E955-64.
14. Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med. 2012; 2012:591654.
15. Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology. 2015 Feb 23;161:69-81.
16. Liang Y, Xu X, Yin M, Zhang Y, Huang L, Chen R, Ni J. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. Endocrine journal. 2019;66(1):51-63.
17. Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One. 2012;7(8):e42529. doi:10.1371/journal.pone.0042529.
18. Sun R, Yang N, Kong B, Cao B, Feng D, Yu X, Ge C, Huang J, Shen J, Wang P, Feng S. Orally administered berberine modulates hepatic lipid metabolism by altering microbial bile acid metabolism and the intestinal FXR signaling pathway. Molecular pharmacology. 2017 Feb 1;91(2):110-22.
19. Liu YT, Hao HP, Xie HG, Lai L, Wang Q, Liu CX, Wang GJ. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug metabolism and disposition. 2010 Oct 1;38(10):1779-84.
20. Ma BL, Ma YM, Shi R, Wang TM, Zhang N, Wang CH, Yang Y. Identification of the toxic constituents in Rhizoma Coptidis. Journal of Ethnopharmacology. 2010 Mar 24;128(2):357-64.
21. Xu M, Deng B, Chow Y, Zhao ZZ, Hu B. Effects of curcumin in treatment of experimental diabetes mellitus: a systematic review and meta-analysis. Pharmacol Res. 2017;122:125-132.
22. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13[4]:251-262.
23. Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, Oh GT, Park HS, Lee KU, Lane MD, Kim JB. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. American Journal of Physiology-Endocrinology and Metabolism. 2009 Apr;296(4):E812-9.
24. Cheng Z, Pang T, Gu M, Gao AH, Xie CM, Li JY, Nan FJ, Li J. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochimica et Biophysica Acta (BBA)-General Subjects. 2006 Nov 1;1760(11):1682-9.
25. Zhou L, Wang X, Shao L, Yang Y, Shang W, Yuan G, Jiang B, Li F, Tang J, Jing H, Chen M. Berberine acutely inhibits insulin secretion from β-cells through 3′, 5′-cyclic adenosine 5′-monophosphate signaling pathway. Endocrinology. 2008 Sep 1;149(9):4510-8.
26. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57[5]:712-717.
27. Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, Wang SK, Zhou ZX, Song DQ, Wang YM, Pan HN. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010 Feb 1;59(2):285-92.
28. Brusq JM, Ancellin N, Grondin P, Guillard R, Martin S, Saintillan Y, Issandou M. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. Journal of lipid research. 2006 Jun 1;47(6):1281-8.
29. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature medicine. 2004 Dec 1;10(12):1344-51.
30. Chang X, Yan H, Fei J, Jiang M, Zhu H, Lu D, Gao X. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats [S]. Journal of lipid research. 2010 Sep 1;51(9):2504-15.
31. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006 Dec 14;444(7121):860-7.
32. Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 2004;203[2]:127-137.
33. Lou T, Zhang Z, Xi Z, Liu K, Li L, Liu B, Huang F. Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. Inflammation. 2011 Dec;34(6):659-67.
34. Zhou H, Feng L, Xu F, Sun Y, Ma Y, Zhang X, Liu H, Xu G, Wu X, Shen Y, Sun Y. Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to insulin resistance improvement. Biomedicine & Pharmacotherapy. 2017 May 1; 89:864-74.
35. Zuo F, Nakamura N, Akao T, Hattori M. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos. 2006;34[12]:2064-2072.
36. Zhang XU, Zhao Y, Xu J, Xue Z, Zhang M, Pang X, Zhang X, Zhao L. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Scientific reports. 2015 Sep 23;5(1):14405.
37. Haiser HJ, Seim KL, Balskus EP, Turnbaugh PJ. Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes. 2014;5[2]:233-238.
38. Tian Y, Cai J, Gui W, Nichols RG, Koo I, Zhang J, Anitha M, Patterson AD. Berberine directly affects the gut microbiota to promote intestinal farnesoid X receptor activation. Drug Metabolism and Disposition. 2019 Feb 1;47(2):86-93.
39. Yin J, Gao Z, Liu D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2008;294[1]:E148-E156.
40. Zhang Y, Gu Y, Ren H, Wang S, Zhong H, Zhao X, Ma J, Gu X, Xue Y, Huang S, Yang J. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nature communications. 2020 Oct 6;11(1):5015.
41. Zhao L, Cang Z, Sun H, Nie X, Wang N, Lu Y. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. BMC Endocr Disord. 2017;17[1]:13.
42. Yin J, Ye J, Jia W. Effects and mechanisms of berberine in diabetes treatment. Acta Pharm Sin B. 2012;2[4]:327-334.
43. Liu L, Yu YL, Yang JS, Li Y, Liu YW, Liang Y, Liu XD, Xie L, Wang GJ. Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn-Schmiedeberg's archives of pharmacology. 2010 Apr;381(4):371-81.
44. Hu Y, Ehli EA, Kittelsrud J, Ronan PJ, Munger K, Downey T, Bohlen K, Callahan L, Munson V, Jahnke M, Marshall LL. Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine. 2012 Jul 15;19(10):861-7.
45. Huang C, Zhang Y, Gong Z, Sheng X, Li Z, Zhang W, Qin Y. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARγ pathway. Biochemical and biophysical research communications. 2006 Sep 22;348(2):571-8.
46. Zhang Z, Zhang H, Li B, Meng X, Wang J, Zhang Y, Yao S, Ma Q, Jin L, Yang J, Wang W. Berberine activates thermogenesis in white and brown adipose tissue. Nature communications. 2014 Nov 25;5(1):5493.
47. Xie W, Gu D, Li J, Cui K, Zhang Y. Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS One. 2011;6[9]:e24520.
48. Wang Y, Shou JW, Li XY, Zhao ZX, Fu J, He CY, Feng R, Ma C, Wen BY, Guo F, Yang XY. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism. 2017 May 1;70:72-84.
49. Wu L, Xia M, Duan Y, Zhang L, Jiang H, Hu X, Yan H, Zhang Y, Gu Y, Shi H, Li J. Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans. Cell death & disease. 2019 Jun 13;10(6):468.
50. Wei W, Zhao H, Wang A, Sui M, Liang K, Deng H, Ma Y, Zhang Y, Zhang H, Guan Y. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European journal of endocrinology. 2012 Jan;166(1):99-105.
51. Cameron J, Ranheim T, Kulseth MA, Leren TP, Berge KE. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis. 2008;201[2]:266-273.
52. Kong WJ, Wei J, Zuo ZY, Wang YM, Song DQ, You XF, Zhao LX, Pan HN, Jiang JD. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism. 2008 Aug 1;57(8):1029-37.
53. Li Y, Ren G, Wang YX, Kong WJ, Yang P, Wang YM, Li YH, Yi H, Li ZR, Song DQ, Jiang JD. Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes. Journal of Translational Medicine. 2011 May 15;9(1):62.
54. Wang X, Wang R, Xing D, Su H, Ma C, Ding Y, Du L. Kinetic difference of berberine between hippocampus and plasma in rat after intravenous administration of Coptidis rhizoma extract. Life Sciences. 2005 Oct 28;77(24):3058-67.
55. Hong Y, Hui SS, Chan BT, Hou J. Effect of berberine on regression of pressure-overload induced cardiac hypertrophy in rats. Am J Chin Med. 2002;30[4]:589-599.
56. Yu L, Li F, Zhao G, Yang Y, Jin Z, Zhai M, Yu W, Zhao L, Chen W, Duan W, Yu S. Protective effect of berberine against myocardial ischemia reperfusion injury: role of Notch1/Hes1-PTEN/Akt signaling. Apoptosis. 2015 Jun;20(6):796-810.
57. Gu Y, Zhang Y, Shi X, Li X, Hong J, Chen J, Gu W, Lu X, Xu G, Ning G. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta. 2010 May 15;81(3):766-72.
58. Zhao W, Xue R, Zhou ZX, Kong WJ, Jiang JD. Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis. Biomed Pharmacother. 2008;62[10]:730-731.
59. Guo Y, Pope C, Cheng X, Zhou H, Klaassen CD. Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice. J Ethnopharmacol. 2011;138[1]:111-118.
60. Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68[2]:213-217.
61. Chen W, Miao YQ, Fan DJ, Yang SS, Lin X, Meng LK, Tang X. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. Aaps Pharmscitech. 2011 Jun;12(2):705-11.
62. Yue SJ, Liu J, Wang AT, Meng XT, Yang ZR, Peng C, Guan HS, Wang CY, Yan D. Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids. American Journal of Physiology-Endocrinology and Metabolism. 2019 Jan 5.
63. Xue M, Yang MX, Zhang W, Li XM, Gao DH, Ou ZM, Li ZP, Liu SH, Li XJ, Yang SY. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. International journal of nanomedicine. 2013 Dec 5:4677-87.
64. Xia X, Weng J. Targeting metabolic syndrome: candidate natural agents. Journal of diabetes. 2010 Dec;2(4):243-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Academic International Journal of Medical Update
This work is licensed under a Creative Commons Attribution 4.0 International License.
